ArticleApplied biochemistry and biotechnology2025
Genetically Engineered Yeast for Enhanced Biodegradation of Β-lactam Antibiotics.
Article in Applied biochemistry and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High environmental concentrations of pharmaceuticals, particularly antibiotics, have been observed worldwide, while antibiotic concentrations in the ng/L to µg/L range may adversely affect biota and contribute to the formation of antibiotic resistance. The underlying causes of high environmental concentrations include, in addition to the low rate of antibiotic' metabolization and the high rate of usage, especially of β-lactam antibiotics, the insufficient removal by conventional wastewater treatment methods. Consequently, alternative methods need to be developed to remove antibiotics from wastewater-one possibility is the use of enzymes. In this study, the enzyme β-lactamase was secreted by a genetically modified yeast (Saccharomyces cerevisiae) upon recognition of a pheromone (α-factor) as inducer to enable the degradation of ampicillin. This represents a crucial step on the road to a sensor-actuator system, allowing for the development of an intelligent removal system that can react to the presence of antibiotics. Ampicillin and its transformation products were studied by LC-MS/MS measurements using a carbamoyl functionalized column under hydrophilic interaction liquid chromatography (HILIC) conditions, which allowed detection of ampicillin at concentrations of 2.43 nM. The dependence of ampicillin degradation on α-factor concentration and the cultivation time of the yeast was demonstrated, resulting in higher degradation rate with higher α-factor concentrations and longer yeast cultivation times. Over 90% of 10 µM ampicillin was degraded within 0.5 h using 250 nM α-factor and a cultivation period of 24 h. Finally, the transferability to other β-lactam antibiotics was investigated, resulting in complete degradation of amoxicillin, penicillin G and piperacillin within 24 h.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.